Reference
Altis K.L, Elwood L.S, & Olatunji B.O. (2015) Ethical Issues and Ethical Therapy Associated with Anxiety Disorders. Curr Top Behav Neurosci; 19:265-78. Retrieved from: https://www.ncbi.nlm.nih.gov/pubmed/
Foa, E. B. (2017). Cognitive behavioral therapy of obsessive-compulsive disorder. Dialogues in Clinical Neuroscience, 12(2), 199–207.Retrieved from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3181959/
Laureate Education (Producer). (2017c). Anxiety disorder, ODC, or something else? [Multimedia file]. Baltimore, MD: Author.
Ordacgi, L., Mendlowicz, M. V., & Fontenelle, L. F. (2017). Management of obsessive-compulsive disorder with fluvoxamine extended release. Neuropsychiatric Disease and Treatment, 5, 301–308.Retrieved from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2699655/
Stahl, S. M. (2014). Prescriber’s Guide: Stahl’s Essential Psychopharmacology (5th
ed.). New York, NY: Cambridge University Press.
Thapar, A., Pine, D. S., Leckman, J. F., Scott, S., Snowling, M. J., & Taylor, E. A. (2015). Rutter’s child and adolescent psychiatry (6th ed.). Hoboken, NJ: Wiley Blackwell.
Decision #3: Treatment Plan for Psychopharmacology
o Why did you select this Decision? Support your response with evidence and references to the Learning Resources.
o What were you hoping to achieve by making this Decision? Support your response with evidence and references to the Learning Resources.
o Explain any difference between what you expected to achieve with Decision #3 and the results of the decision. Why were they different?
• Also include how ethical considerations might impact your treatment plan and communication with clients and their families.
The Case study: Anxiety disorder, OCD, or something else?
BACKGROUND
